Combining topical finasteride with RU58841 for hair loss treatment. Users discuss the effectiveness and potential side effects of oral and topical finasteride.
A user is considering using topical finasteride, topical minoxidil, RU58841, and dermarolling twice a week to address hair loss after experiencing side effects with oral finasteride. They previously saw positive results with a topical spray containing finasteride, minoxidil, and tretinoin but discontinued use due to laziness.
User experienced side effects from topical finasteride, including penile pain and reduced sexual satisfaction, and is unsure whether to resume or avoid the treatment. They are seeking advice on whether tapering off the drug might help.
Intermittent finasteride dosing, like taking it every third day, may reduce side effects while still lowering DHT levels. Users report side effects such as brain fog and weaker erections, which often subside after stopping the drug.
A user suggests using a poop-based solution for hair growth, comparing it to fertilizing nails. Others humorously respond, with one mentioning microneedling as a similar concept.
The conversation is about using a DHT-blocking supplement alongside finasteride for hair loss. The user decided against the supplement and increased their finasteride dose from 1 mg to 2.5 mg per day.
Switching to Amazon for finasteride prescriptions can save money, with a 90-day supply costing around $17 for Prime members. Oral minoxidil requires monitoring, so a local doctor is needed for that prescription.
The user is considering switching from finasteride to oral dutasteride due to side effects and lack of regrowth. They are unable to access topical dutasteride and are seeking advice on whether to proceed with oral dutasteride.
The user takes 1 mg finasteride three times a week, topical minoxidil daily, and Saw Palmetto both topically and orally on non-finasteride days. They recently added 1 g of pumpkin seed oil daily to improve hair thickness and are seeking advice on dosing and cycling Saw Palmetto.
The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.
A user is creating a custom topical hair regrowth serum using minoxidil, bimatoprost, tretinoin, castor oil, and hyaluronic acid. They are also using dutasteride, oral minoxidil, and castor oil in their current regimen.
The user is seeking advice on effectively applying a liposomal solution of Minoxidil and Finasteride for hair loss, specifically targeting the roots without wasting the product. They find it challenging to use only 1 ml to cover thinning areas on the front and crown.
New hair loss treatments like GT20029, Clascoterone, and PP405 are being discussed, with concerns about how to apply multiple topicals alongside existing treatments like minoxidil and finasteride. Suggestions include creating a routine, mixing treatments, or minimizing redundancy in treatment stacks.
The conversation is about a user switching from finasteride to dutasteride after 4 years due to continued hair recession and miniaturization. The user plans to gradually increase to 1mg of dutasteride daily.
Dutasteride mesotherapy is discussed as a potentially effective hair loss treatment with no sexual side effects, requiring less frequent application than daily pills. However, it is not widely popular due to limited availability, high cost, and skepticism about its effectiveness.
The user is using a regimen of topical Minoxidil and Finasteride, oral Minoxidil, and a thickening shampoo and conditioner. They report no side effects except increased body hair, which they don't mind.
Topical Dutasteride is more effective than topical Finasteride for treating AGA in men, with fewer side effects. Mesotherapy with Dutasteride, administered every 3 months, shows promising results for hair regrowth and maintenance without daily routines or significant side effects.
The user is taking 1mg finasteride daily and RU58841 5% but still experiencing hair loss. They are considering adding topical finasteride or switching to dutasteride, and are not planning to use minoxidil until hair loss stabilizes.
PP405 is a potential hair loss treatment showing promising early results, with hopes for market release by 2028, but skepticism remains due to inconclusive data and past disappointments with similar products. Current treatments like Minoxidil and Finasteride have side effects, leading some to anticipate PP405 as a safer alternative, though its effectiveness compared to placebo is debated.
The user is considering switching from oral to topical minoxidil due to lack of improvement and side effects, while continuing with dutasteride or finasteride. They seek advice from others with diffuse thinning.
The user experienced severe side effects when using topical Dutasteride and RU58841 together and is considering using them at different times of the day. They are seeking advice on whether this approach might reduce side effects.
The conversation discusses various methods for applying topical minoxidil to the scalp, including using fingers, a shoe polish bottle, a dropper, a toothbrush, a q-tip, a makeup brush, and a syringe. Users emphasize the importance of massaging the product into the scalp for better absorption.
The conversation discusses the ineffectiveness of dutasteride in halting hair loss for the user and explores the potential of PP405, which works through a different mechanism. Suggestions include considering a biopsy to determine the cause of hair loss and exploring other treatments like RU58841.
GT20029 and PP405 are discussed as potential alternatives or complements to finasteride for hair loss treatment. GT20029 is entering phase 3 trials, while PP405 is seen as promising for regrowing hair and possibly eliminating the need for other treatments.
Switching from 2% liquid minoxidil to 5% foam minoxidil reduced scalp irritation but increased eyebrow flakiness and thinning. The user speculates that propylene glycol in the liquid formulation might have been protecting against seborrheic dermatitis while causing contact dermatitis.
Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.
The conversation is about adding a topical anti-androgen to a hair loss treatment regimen that includes dutasteride and oral minoxidil. The user is considering topical finasteride or dutasteride, Nizoral shampoo, KX-826, and topical spironolactone, while avoiding RU58841 due to safety concerns.
Anageninc stopping the sale of Pyrilutamide due to a cease and desist order from Kintor, with some speculating that it was either a hoax or subpar product.